The Adalimumab Free Anti-Drug Antibody ELISA is intended for the semi-quantitative determination of free anti-drug antibodies against Humira® in human serum and EDTA plasma. Research Use Only. Not for Use in Diagnostic Procedures.
Item 30-ADFHU-E01 is no longer available. An automated CLIA assay is coming soon. To receive updates on the replacement product, please submit this brief form.
This enzyme immunoassay is a sandwich assay for the semi-quantitative determination of free antibodies against adalimumab (e. g. HUMIRA®). In a first incubation step, the free antitherapeutic antibodies from the sample are bound to the adalimumab F(ab)2 fragments coated on the plate. To remove all unbound substances, a washing step is carried out. In a further incubation step, peroxidase-labeled adalimumab is added. After another washing step, to remove all unbound substances, the solid phase is incubated with the substrate, tetramethylbenzidine (TMB). An acidic stop solution is then added. The color converts to yellow. The absorbance of the color compound is determined photometrically. The intensity of the color is directly proportional to the amount of bound ADAs (here: anti-adalimumab antibodies) from the sample. The results are evaluated by a cut-off control.
1. What percentage of your IgE allergy testing panel consists of molecular allergens rather than allergen extracts? The ALEX2 IgE allergen panel consists of 117 extracts and 183 molecular allergens. This represents the largest panel of molecular allergens on the market, including 50 unique...
Cases of food and environmental allergies have been increasing over the last decade. While conservative estimates suggest IgE-mediated allergy affects 6-8% of children and 2-3% of adults, some estimates are as high as 30%.3, 2 Symptoms can range from mild to severe and include itching, hives,...
Food sensitivity or food intolerance involves a non-allergic response to a food or food additive. In a recent on-line survey conducted in the U.S., 24% of adults aged 18 to 79 reported a food intolerance. While a food allergy is typically mediated by IgE antibodies, adverse reactions to food...
In a head-to-head comparison of FDA-cleared assays and a novel ALPCO method, investigators observed wide variability in specificity and false-positive rates across platforms, raising important questions about standardization and clinical interpretation.
July 22, 2025 – Salem, NH – NuvinkaDx, a leading innovator in diagnostic solutions, today announced two significant product and regulatory milestones from its operating companies, GeneProof and ALPCO.
Energy homeostasis is a focus of research into diabetes and obesity. Read about how our assays in this area can assist both academic and industry researchers.
Complement System Solutions for Drug Development and Clinical Research Datasheet
The complement system is essential to innate immunity from a variety of diseases. ALPCO’s full range of complement system immunoassays can drive discovery.
Melatonin Products for Sleep Disorder-Related Research Datasheet
The melatonin hormone affects the circadian rhythm and sleep-wake cycle. Find out about our immunoassays and products that explore melatonin and sleep disorders.
